Kamada seeks to begin phase 1/2 clinical trials for coronavirus vaccine

Its plasma-derived immunoglobulin (IgG) product for the coronavirus acts a sort of passive vaccine, and functions by trying to using antibodies found in the blood plasma from recovered patients. https://www.jpost.com/health-science/kamada-seeks-to-begin-phase-12-clinical-trials-for-coronavirus-vaccine-631805